Brian O'Sullivan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1862867/publications.pdf

Version: 2024-02-01

283 papers	23,340 citations	8755 75 h-index	9103 144 g-index
358 all docs	358 docs citations	358 times ranked	20808 citing authors

#	Article	IF	Citations
1	Treatment outcomes and survival following definitive (chemo)radiotherapy in <scp>HPV</scp>â€positive oropharynx cancer: Largeâ€scale comparison of <scp>DAHANCA</scp> vs <scp>PMH</scp> cohorts. International Journal of Cancer, 2022, 150, 1329-1340.	5.1	8
2	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiotherapy and Oncology, 2022, 167, 179-186.	0.6	8
3	Risk Stratification of HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Are All Tumors Created Equally?. Current Otorhinolaryngology Reports, 2022, 10, 68.	0.5	0
4	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel. Oncologist, 2022, 27, 4-6.	3.7	4
5	Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology, 2022, 125, 105716.	1.5	5
6	Refining TNM-8ÂM1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncology, 2022, 126, 105736.	1.5	4
7	Radiologicâ€"pathologic correlation of major versus minor extranodal extension in oral cavity cancer. Head and Neck, 2022, 44, 1422-1429.	2.0	3
8	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. JAMA Otolaryngology - Head and Neck Surgery, 2022, , .	2.2	1
9	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. Cancers, 2022, 14, 1923.	3.7	1
10	Clinical presentation and outcome of human papillomavirusâ€positive nasopharyngeal carcinoma in a North American cohort. Cancer, 2022, 128, 2908-2921.	4.1	10
11	Prognostic factors in sinonasal cancers: A multicenter pooled analysis.. Journal of Clinical Oncology, 2022, 40, 6092-6092.	1.6	0
12	Augmenting interâ€rater concordance of radiologic extranodal extension in <scp>HPV</scp>â€positive oropharyngeal carcinoma: A multicenter study. Head and Neck, 2022, 44, 2361-2369.	2.0	5
13	Preâ€and Postâ€Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. Laryngoscope, 2021, 131, E1162-E1171.	2.0	9
14	Shortâ€term and longâ€term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head and Neck, 2021, 43, 456-466.	2.0	1
15	Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma. Radiotherapy and Oncology, 2021, 156, 95-101.	0.6	2
16	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiotherapy and Oncology, 2021, 154, 70-75.	0.6	23
17	Presence and duration of feeding tube in a 5â€year cohort of patients with head and neck cancer treated with curative i<scp>ntensityâ€modulated</scp> radiation therapy. Head and Neck, 2021, 43, 1610-1620.	2.0	5
18	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. Oral Oncology, 2021, 114, 105167.	1.5	11

#	Article	IF	Citations
19	Statistical fundamentals on cancer research for clinicians: Working with your statisticians. Clinical and Translational Radiation Oncology, 2021, 27, 75-84.	1.7	2
20	Assessment Criteria and Clinical Implications of Extranodal Extension in Head and Neck Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 265-278.	3.8	35
21	Editorial: Advances in the Pathogenesis and Therapeutic Strategies for Nasopharyngeal Carcinoma. Frontiers in Oncology, 2021, 11, 647809.	2.8	5
22	Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). Journal of Clinical Oncology, 2021, 39, 956-965.	1.6	195
23	Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey. Oral Oncology, 2021, 114, 105165.	1.5	5
24	Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiotherapy and Oncology, 2021, 157, 114-121.	0.6	32
25	Importance of Margins, Radiotherapy, and Systemic Therapy in Mucosal Melanoma of the Head and Neck. Laryngoscope, 2021, 131, 2269-2276.	2.0	9
26	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. Radiotherapy and Oncology, 2021, 157, 255-262.	0.6	4
27	Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2021, 39, 6046-6046.	1.6	0
28	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncology, The, 2021, 22, 727-736.	10.7	45
29	A costâ€utility analysis comparing CT surveillance, PETâ€CT surveillance, and planned postradiation neck dissection for advanced nodal HPVâ€positive oropharyngeal cancer. Cancer, 2021, 127, 3372-3380.	4.1	5
30	Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1227-1236.	0.8	5
31	Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. Frontiers in Oncology, 2021, 11, 703995.	2.8	25
32	Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. Oral Oncology, 2021, 120, 105419.	1.5	4
33	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiotherapy and Oncology, 2021, 165, 94-102.	0.6	22
34	Examining the Landscape of Prognostic Factors and Clinical Outcomes for Cancer Control. Current Oncology, 2021, 28, 5155-5166.	2.2	0
35	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. Radiotherapy and Oncology, 2020, 144, 13-22.	0.6	30
36	The role of adjuvant (chemo-)radiotherapy in oral cancers in the contemporary era. Oral Oncology, 2020, 102, 104563.	1.5	14

#	Article	IF	Citations
37	Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020, 126, 5263-5273.	4.1	11
38	Sexual satisfaction in nasopharyngeal carcinoma survivors: Rates and determinants. Oral Oncology, 2020, 109, 104865.	1.5	4
39	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. Radiotherapy and Oncology, 2020, 153, 97-105.	0.6	19
40	Potential therapeutic implications of the new tumor, node, metastasis staging system for human papillomavirus-mediated oropharyngeal cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 100-106.	1.8	1
41	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVIDâ€19 pandemic: The Princess Margaret experience and proposal. Cancer, 2020, 126, 3426-3437.	4.1	42
42	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Scientific Reports, 2020, 10, 4542.	3.3	46
43	Alpha Test of Intelligent Machine Learning in Staging Head and Neck Cancer. Journal of Clinical Oncology, 2020, 38, 1255-1257.	1.6	7
44	User-controlled pipelines for feature integration and head and neck radiation therapy outcome predictions. Physica Medica, 2020, 70, 145-152.	0.7	14
45	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. Clinical and Translational Radiation Oncology, 2020, 21, 69-76.	1.7	1
46	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. Oral Oncology, 2020, 105, 104666.	1.5	8
47	Global Consultation on Cancer Staging: promoting consistent understanding and use. Nature Reviews Clinical Oncology, 2019, 16, 763-771.	27.6	52
48	Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma. Oral Oncology, 2019, 99, 104438.	1.5	43
49	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.8	96
50	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. Oral Oncology, 2019, 97, 124-130.	1.5	2
51	Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiotherapy and Oncology, 2019, 134, 1-9.	0.6	132
52	The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in lowâ€risk HPVâ€related oropharyngeal cancer in a realâ€world setting. Head and Neck, 2019, 41, 2271-2276.	2.0	8
53	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirusâ€"Mediated Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1017-1027.	0.8	50
54	Depicting distant metastatic risk by refined subgroups derived from the 8th edition nasopharyngeal carcinoma TNM. Oral Oncology, 2019, 91, 113-120.	1.5	8

#	Article	IF	Citations
55	Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy. Radiotherapy and Oncology, 2019, 134, 10-16.	0.6	8
56	The addition of pretreatment plasma Epsteinâ€"Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. International Journal of Cancer, 2019, 144, 1713-1722.	5.1	82
57	Vulnerabilities of radiomic signature development: The need for safeguards. Radiotherapy and Oncology, 2019, 130, 2-9.	0.6	233
58	¹⁸Fâ€FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A metaâ€analysis of reported studies. Head and Neck, 2019, 41, 551-561.	2.0	24
59	Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. Clinical and Translational Radiation Oncology, 2019, 15, 13-19.	1.7	7
60	Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 363-373.	0.8	38
61	Data Set for the Reporting of Carcinomas of the Nasopharynx and Oropharynx: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. Archives of Pathology and Laboratory Medicine, 2019, 143, 447-451.	2.5	5
62	A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. Radiotherapy and Oncology, 2019, 131, 179-185.	0.6	38
63	Impact of tobacco smoking on radiotherapy outcomes in 1875 HPV-positive oropharynx cancer patients.. Journal of Clinical Oncology, 2019, 37, 6047-6047.	1.6	3
64	Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.. Journal of Clinical Oncology, 2019, 37, 6085-6085.	1.6	1
65	Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive chemoradiotherapy.. Journal of Clinical Oncology, 2019, 37, 6046-6046.	1.6	0
66	Immune signature and molecular profiling of radiation-induced sarcoma (RIS).. Journal of Clinical Oncology, 2019, 37, 11040-11040.	1.6	3
67	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1107-1116.	0.8	57
68	Proteomic Analysis of Cancer-Associated Fibroblasts Reveals a Paracrine Role for MFAP5 in Human Oral Tongue Squamous Cell Carcinoma. Journal of Proteome Research, 2018, 17, 2045-2059.	3.7	65
69	Partial Laryngeal IMRT for T2N0 Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 941-949.	0.8	17
70	Evidence-based region of interest matching guidelines for sarcoma volumetric image-guided radiation therapy. Technical Innovations and Patient Support in Radiation Oncology, 2018, 5, 3-8.	1.9	2
71	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. British Journal of Radiology, 2018, 91, 20170498.	2.2	109
72	Sclerosing Epithelioid Fibrosarcoma of the Jaw: Late Recurrence from a Low Grade Fibromyxoid Sarcoma. Head and Neck Pathology, 2018, 12, 619-622.	2.6	10

#	Article	IF	Citations
73	Skull base or cervical vertebral osteomyelitis following chemoradiotherapy for pharyngeal carcinoma: A serious but treatable complication. Clinical and Translational Radiation Oncology, 2018, 8, 40-44.	1.7	10
74	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy and Oncology, 2018, 126, 3-24.	0.6	244
75	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. Seminars in Radiation Oncology, 2018, 28, 17-26.	2.2	16
76	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2018, 126, 25-36.	0.6	214
77	Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. Journal of Clinical Oncology, 2018, 36, 704-709.	1.6	155
78	Major Changes in Head and Neck Staging for 2018. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 505-514.	3.8	60
79	The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right. Oral Oncology, 2018, 86, 171-180.	1.5	15
80	Radiologic-Pathologic Correlation of Tumor Thickness and Its Prognostic Importance in Squamous Cell Carcinoma of the Oral Cavity: Implications for the Eighth Edition Tumor, Node, Metastasis Classification. American Journal of Neuroradiology, 2018, 39, 1896-1902.	2.4	40
81	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 698-708.	0.8	48
82	Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma. Oral Oncology, 2018, 82, 162-167.	1.5	9
83	Preoperative Radiation Therapy for Locally Advanced Sinus Malignancies. International Journal of Radiation Oncology Biology Physics, 2018, 101, 763-764.	0.8	0
84	Surgery- vs Radiation-Based Therapy for p16+/HPV-Related Oropharyngeal Cancers. Current Otorhinolaryngology Reports, 2018, 6, 298-309.	0.5	4
85	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 71-79.	2.2	26
86	Human Papillomavirus and Head and Neck Cancer. , 2018, , 167-181.		0
87	Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology Biology Physics, 2017, 97, 678-686.	0.8	41
88	Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). European Journal of Cancer, 2017, 72, 192-199.	2.8	18
89	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25ÂYears Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 159-169.	0.8	61
90	Head and neck cancersâ€"major changes in the American Joint Committee on cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 122-137.	329.8	1,137

#	Article	IF	Citations
91	Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 170-176.	0.8	7
92	The value of adaptive preoperative radiotherapy in management of soft tissue sarcoma. Radiotherapy and Oncology, 2017, 122, 458-463.	0.6	17
93	An Analysis of Tumor- and Surgery-Related Factors that Contribute to Inadvertent Positive Margins Following Soft Tissue Sarcoma Resection. Annals of Surgical Oncology, 2017, 24, 2137-2144.	1.5	21
94	Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head and Neck, 2017, 39, 1205-1211.	2.0	42
95	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 858-867.	0.8	19
96	Morphologic and topographic radiologic features of human papillomavirusâ€related and â€“unrelated oropharyngeal carcinoma. Head and Neck, 2017, 39, 1524-1534.	2.0	37
97	Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Current Treatment Options in Oncology, 2017, 18, 40.	3.0	455
98	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensityâ€modulated radiotherapy. Cancer, 2017, 123, 3691-3700.	4.1	99
99	Body mass index and prognosis in patients with head and neck cancer. Head and Neck, 2017, 39, 1226-1233.	2.0	64
100	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 368.	2.2	19
101	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. JAMA Oncology, 2017, 3, 220.	7.1	64
102	Setting the Stage for 2018: How the Changes in the American Joint Committee on Cancer/Union for International Cancer ControlCancer Staging ManualEighth Edition Impact Radiologists. American Journal of Neuroradiology, 2017, 38, 2231-2237.	2.4	40
103	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. Radiotherapy and Oncology, 2017, 124, 225-231.	0.6	33
104	Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPVâ˜ve Oropharynx cancer? A population-based study. British Journal of Cancer, 2017, 117, 1105-1112.	6.4	10
105	Impact of Type 2 Diabetes Mellitus on Survival in Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2017, 157, 657-663.	1.9	11
106	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncology, The, 2017, 18, 1221-1237.	10.7	226
107	Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. Cmaj, 2017, 189, E1030-E1040.	2.0	40
108	Outcome following radiotherapy for head and neck basal cell carcinoma with â€˜aggressiveâ€™ features. Oral Oncology, 2017, 72, 157-164.	1.5	15

#	Article	IF	Citations
109	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10â€year outcomes for efficacy and toxicity. Cancer, 2017, 123, 4147-4157.	4.1	70
110	The TNM classification of malignant tumoursâ€"towards common understanding and reasonable expectations. Lancet Oncology, The, 2017, 18, 849-851.	10.7	164
111	Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 709-717.	0.8	31
112	The principles of cancer staging. Ecancermedicalscience, 2016, 10, ed61.	1.1	47
113	The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer Biology and Medicine, 2016, 13, 373-383.	3.0	28
114	Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. Head and Neck, 2016, 38, E1102-9.	2.0	39
115	Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma. Laryngoscope, 2016, 126, 2270-2275.	2.0	33
116	Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. Head and Neck, 2016, 38, E1688-94.	2.0	28
117	Clinical outcomes in patients with T4 laryngeal cancer treated with primary radiotherapy versus primary laryngectomy. Head and Neck, 2016, 38, E2035-40.	2.0	29
118	Proposal for the 8th edition of the <scp>AJCC</scp>/<scp>UICC</scp> staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 546-558.	4.1	254
119	Valid and reliable techniques for measuring fibrosis in patients with head and neck cancer postradiotherapy: A systematic review. Head and Neck, 2016, 38, E2322-34.	2.0	12
120	Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma. Head and Neck, 2016, 38, 1347-1353.	2.0	31
121	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Investigational New Drugs, 2016, 34, 575-583.	2.6	9
122	A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. Cancer Epidemiology, 2016, 42, 173-180.	1.9	4
123	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2016, 67, 174-182.	2.8	75
124	The Challenges of Treatment Adaptation and De-intensification in Human Papillomavirusâ€"Positive Oropharyngeal Cancer: The Difficult Journey Back. International Journal of Radiation Oncology Biology Physics, 2016, 96, 18-20.	0.8	5
125	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. Oral Oncology, 2016, 59, 43-49.	1.5	16
126	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 3307-3315.	4.1	125

#	Article	IF	Citations
127	Health-related quality of life following treatment for extremity soft tissue sarcoma. Journal of Surgical Oncology, 2016, 114, 821-827.	1.7	16
128	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 1208.	2.2	20
129	Salvage surgery for locally recurrent oropharyngeal cancer. Head and Neck, 2016, 38, E658-64.	2.0	66
130	Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head and Neck, 2016, 38, E820-6.	2.0	82
131	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncology, 2016, 54, 75-80.	1.5	56
132	Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiotherapy and Oncology, 2016, 119, 14-21.	0.6	72
133	Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 823.	7.1	98
134	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncology, The, 2016, 17, 440-451.	10.7	607
135	Head and Neck Cancer Staging and Prognosis: Perspectives of the UICC and the AJCC. , 2016, , 181-203.		3
136	The impact of multimodality therapy in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program Experience.. Journal of Clinical Oncology, 2016, 34, 11051-11051.	1.6	0
137	Did the addition of chemotherapy to conventional radiotherapy improve outcomes in treatment of oropharynx cancer in Ontario, Canada? A marker-treatment interaction study.. Journal of Clinical Oncology, 2016, 34, e17533-e17533.	1.6	0
138	Hyperfractionated or accelerated radiotherapy for head and neck cancer. The Cochrane Library, 2015, 2015, .	2.8	52
139	Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. Journal of Otolaryngology - Head and Neck Surgery, 2015, 44, 43.	1.9	37
140	Longer survival in patients with human papillomavirusâ€"related head and neck cancer after positive postradiation planned neck dissection. Head and Neck, 2015, 37, 946-952.	2.0	14
141	Impact of the addition of chemotherapy to radiotherapy for oropharyngeal cancer in 2003â€"2004: Populationâ€based study from the Province of Ontario, Canada. Head and Neck, 2015, 37, 1461-1469.	2.0	5
142	Adjuvant Radiation for Soft Tissue Sarcomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e634-e642.	3.8	8
143	Extra-pulmonary small cell carcinoma in the head and neck setting: The role of prophylactic cranial irradiation. Oral Oncology, 2015, 51, e57-e59.	1.5	5
144	Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. International Journal of Radiation Oncology Biology Physics, 2015, 92, 602-612.	0.8	102

#	Article	IF	Citations
145	Reply to J.J. Beitler et al. Journal of Clinical Oncology, 2015, 33, 3218-3219.	1.6	1
146	Comparison of Health State Utility Measures in Patients With Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 696.	2.2	47
147	No evidence for improved TORS post-treatment feeding tube dependency rate relative to standard therapy in early stage oropharyngeal cancer. Oral Oncology, 2015, 51, e67.	1.5	0
148	Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. Neuro-Oncology, 2015, 17, 889-894.	1.2	93
149	Current Status of Clinical Trials in Head and Neck Cancer 2014. Otolaryngology - Head and Neck Surgery, 2015, 152, 410-417.	1.9	8
150	Novel Insights into Head and Neck Cancer using Next-Generation â€œOmicâ€•Technologies. Cancer Research, 2015, 75, 480-486.	0.9	49
151	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirusâ€"Related Oropharyngeal Carcinomas. Journal of Clinical Oncology, 2015, 33, 836-845.	1.6	345
152	Principles of Cancer Staging for Clinical Obstetrics and Gynecology. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 767-775.	2.8	6
153	The Influence of Time Interval Between Preoperative Radiation and Surgical Resection on the Development of Wound Healing Complications in Extremity Soft Tissue Sarcoma. Annals of Surgical Oncology, 2015, 22, 2824-2830.	1.5	40
154	A multiâ€institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensityâ€modulated radiotherapy. Cancer, 2015, 121, 294-301.	4.1	109
155	The Effect of Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement on Swallowing and Swallow-Related Outcomes in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Systematic Review. Dysphagia, 2015, 30, 152-175.	1.8	58
156	Expanding global access to radiotherapy. Lancet Oncology, The, 2015, 16, 1153-1186.	10.7	709
157	External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta OncolÃ³gica, 2015, 54, 1423-1429.	1.8	195
158	CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology, 2015, 117, 83-90.	0.6	425
159	First Site of Failure Analysis Incompletely Addresses Issues of Late and Unexpected Metastases in p16-Positive Oropharyngeal Cancer. Journal of Clinical Oncology, 2015, 33, 1707-1708.	1.6	18
160	Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. Head and Neck, 2015, 37, 655-661.	2.0	30
161	Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer, 2015, 121, 545-555.	4.1	133
162	Local control following resection of primary retroperitoneal sarcoma with and without preoperative radiotherapy.. Journal of Clinical Oncology, 2015, 33, 10572-10572.	1.6	2

#	Article	IF	Citations
163	Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget, 2015, 6, 4537-4550.	1.8	50
164	Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. Oncotarget, 2015, 6, 39127-39139.	1.8	14
165	Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e98557.	2.5	11
166	Integrated Omic Analysis of Oropharyngeal Carcinomas Reveals Human Papillomavirus (HPV)â€"dependent Regulation of the Activator Protein 1 (AP-1) Pathway. Molecular and Cellular Proteomics, 2014, 13, 3572-3584.	3.8	19
167	Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status. Head and Neck, 2014, 36, 802-810.	2.0	69
168	Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: Long-term results of a prospective trial. Radiotherapy and Oncology, 2014, 110, 165-171.	0.6	83
169	Outcome following IMRT for T2 glottic cancer: the potential impact of image-guidance protocols on local control. Journal of Radiation Oncology, 2014, 3, 267-275.	0.7	6
170	Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology, 2014, 110, 172-181.	0.6	585
171	The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer, 2014, 120, 2866-2875.	4.1	139
172	Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy. Radiotherapy and Oncology, 2014, 112, 308-313.	0.6	19
173	Phase 2 study of preoperative imageâ€guided intensityâ€modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer, 2013, 119, 1878-1884.	4.1	187
174	Temporal Nodal Regression and Regional Control After Primary Radiation Therapy for N2-N3 Head-and-Neck Cancer Stratified by HPV Status. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1078-1085.	0.8	100
175	Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. Oral Oncology, 2013, 49, 407-412.	1.5	36
176	Response to Letter to the Editor with Reference to article â€œPostoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failureâ€. Oral Oncology, 2013, 49, e19.	1.5	1
177	Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. Cancer, 2013, 119, 2701-2709.	4.1	51
178	The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. Cancer Epidemiology, 2013, 37, 820-829.	1.9	42
179	Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure. Oral Oncology, 2013, 49, 255-260.	1.5	49
180	Imaging and resectability issues of sinonasal tumors. Expert Review of Anticancer Therapy, 2013, 13, 297-312.	2.4	17

#	Article	IF	Citations
181	Oral cancer: Current role of radiotherapy and chemotherapy. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2013, 18, e233-e240.	1.7	230
182	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncology, 2013, 49, 79-85.	1.5	239
183	Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. Carcinogenesis, 2013, 34, 1012-1017.	2.8	29
184	A Pragmatic Contouring Guideline for Salivary Gland Structures in Head and Neck Radiation Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 70-76.	1.3	19
185	Potentially Prognostic miRNAs in HPV-Associated Oropharyngeal Carcinoma. Clinical Cancer Research, 2013, 19, 2154-2162.	7.0	99
186	Deintensification Candidate Subgroups in Human Papillomavirusâ€"Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. Journal of Clinical Oncology, 2013, 31, 543-550.	1.6	551
187	Identification of a recurrent transforming UBR5â€"ZNF423 fusion gene in EBV â€associated nasopharyngeal carcinoma. Journal of Pathology, 2013, 231, 158-167.	4.5	43
188	Longâ€term regional control and survival in patients with â€œlowâ€risk,â€•early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation. Cancer, 2013, 119, 1168-1176.	4.1	189
189	MicroRNA-193b Enhances Tumor Progression via Down Regulation of Neurofibromin 1. PLoS ONE, 2013, 8, e53765.	2.5	53
190	Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 2012, 18, 1798-1807.	7.0	56
191	Progressive Tumefactive Fibroinflammatory Lesion of the Infratemporal Fossa Treated by Radiation Therapy. Rare Tumors, 2012, 4, 32-36.	0.6	9
192	Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?. Lancet Oncology, The, 2012, 13, e292-e300.	10.7	96
193	Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 276-283.	0.8	207
194	The Relationship Between Local Recurrence and Radiotherapy Treatment Volume for Soft Tissue Sarcomas Treated With External Beam Radiotherapy and Function Preservation Surgery. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1528-1534.	0.8	27
195	In regard to RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume and Clinical Target Volume on Computed Tomographic Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in Radiation Therapy Oncology Group Studies: In regard to Wang etÂal (Int J Radiat Oncol Biol Phys 2011;81:e525â€"e528). International Journal of Radiation Oncology Biology Physics, 2012, 83, 483.	0.8	5
196	Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where?. International Journal of Radiation Oncology Biology Physics, 2012, 84, 572-580.	0.8	185
197	The Effect of Registration Volume Extent on Residual Errors Assessed Using Cone-Beam Computed Tomography in Radiation Treatment of Head and Neck Cancer. Journal of Medical Imaging and Radiation Sciences, 2012, 43, 95-102.	0.3	1
198	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiotherapy and Oncology, 2012, 103, 49-56.	0.6	167

#	Article	IF	Citations
199	Radiation Therapy for Infiltrative Giant Cell Tumor of the Tendon Sheath. Journal of Hand Surgery, 2012, 37, 775-782.	1.6	11
200	Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6â€“7, 2011, Arlington, Virginia. Head and Neck, 2012, 34, 1681-1703.	2.0	90
201	Potentially Novel Candidate Biomarkers for Head and Neck Squamous Cell Carcinoma Identified Using an Integrated Cell Line-based Discovery Strategy. Molecular and Cellular Proteomics, 2012, 11, 1404-1415.	3.8	55
202	Squamous cell carcinoma of the buccal mucosa: Outcomes of Treatment in the modern era. Laryngoscope, 2012, 122, 1552-1557.	2.0	30
203	Patterns of failure and histopathologic outcome predictors following definitive radiotherapy and planned neck dissection with residual disease. Head and Neck, 2012, 34, 913-922.	2.0	12
204	Longâ€term outcome of the treatment of highâ€risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery. Cancer, 2012, 118, 4901-4909.	4.1	71
205	The clinical and functional outcome for patients with radiationâ€induced soft tissue sarcoma. Cancer, 2012, 118, 2682-2692.	4.1	67
206	Local recurrence of localized soft tissue sarcoma. Cancer, 2012, 118, 5867-5877.	4.1	100
207	Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02.. Journal of Clinical Oncology, 2012, 30, 5571-5571.	1.6	1
208	Soft Tissue Sarcoma. , 2012, , 1355-1391.		1
209	Caspase 3â€“mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine, 2011, 17, 860-866.	30.7	705
210	Factors contributing to the efficacy of concurrentâ€“adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials. European Journal of Cancer, 2011, 47, 656-666.	2.8	196
211	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2011, 98, 15-22.	0.6	102
212	Retrospective Study of Palliative Radiotherapy in Newly Diagnosed Head and Neck Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 958-963.	0.8	48
213	A population-based study of factors associated with early versus late stage oral cavity cancer diagnoses. Oral Oncology, 2011, 47, 642-647.	1.5	59
214	Soft tissue sarcoma presenting with metastatic disease. Cancer, 2011, 117, 372-379.	4.1	64
215	Highâ€risk extracranial chondrosarcoma. Cancer, 2011, 117, 2513-2519.	4.1	42
216	Patterns of Care in Elderly Head-and-Neck Cancer Radiation Oncology Patients: A Single-Center Cohort Study. International Journal of Radiation Oncology Biology Physics, 2011, 79, 46-51.	0.8	77

#	Article	IF	Citations
217	Cognitive Functioning After Radiotherapy or Chemoradiotherapy for Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 126-134.	0.8	78
218	In Reply Drs. Delaney and Chen. International Journal of Radiation Oncology Biology Physics, 2011, 80, 959-960.	0.8	0
219	miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. Cancer Research, 2011, 71, 2381-2391.	0.9	258
220	Significance of Dysregulated Metadherin and MicroRNA-375 in Head and Neck Cancer. Clinical Cancer Research, 2011, 17, 7539-7550.	7.0	82
221	Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma. Sarcoma, 2011, 2011, 1-6.	1.3	38
222	Adverse Effect of Older Age on the Recurrence of Soft Tissue Sarcoma of the Extremities and Trunk. Journal of Clinical Oncology, 2011, 29, 4029-4035.	1.6	47
223	Uroporphyrinogen Decarboxylase Is a Radiosensitizing Target for Head and Neck Cancer. Science Translational Medicine, 2011, 3, 67ra7.	12.4	32
224	Axial Skeletal Location Predicts Poor Outcome in Ewing's Sarcoma: A Single Institution Experience. Sarcoma, 2011, 2011, 1-5.	1.3	9
225	Significance of Plk1 regulation by miRâ€100 in human nasopharyngeal cancer. International Journal of Cancer, 2010, 126, 2036-2048.	5.1	126
226	Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. European Archives of Oto-Rhino-Laryngology, 2010, 267, 295-301.	1.6	67
227	Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh. Cancer, 2010, 116, 1553-1559.	4.1	65
228	Clinical outcome of children and adults with localized Ewing sarcoma. Cancer, 2010, 116, 3189-3194.	4.1	96
229	Positive Surgical Margins in Soft Tissue Sarcoma Treated With Preoperative Radiation: Is a Postoperative Boost Necessary?. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1191-1197.	0.8	118
230	Cone-Beam CT Assessment of Interfraction and Intrafraction Setup Error of Two Head-and-Neck Cancer Thermoplastic Masks. International Journal of Radiation Oncology Biology Physics, 2010, 76, 949-955.	0.8	63
231	Measuring Interfractional and Intrafractional Motion With Cone Beam Computed Tomography and an Optical Localization System for Lower Extremity Soft Tissue Sarcoma Patients Treated With Preoperative Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1437-1444.	0.8	38
232	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology, 2010, 28, 2989-2995.	1.6	339
233	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2010, 102, 1188-1198.	6.3	298
234	Magnetic resonance imaging of nasopharyngeal carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 365-375.	2.4	20

#	Article	IF	Citations
235	Prognostic Significance of p16^{INK4A} and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology, 2010, 28, 4142-4148.	1.6	679
236	Nasopharyngeal carcinoma: The next challenges. European Journal of Cancer, 2010, 46, 1967-1978.	2.8	201
237	Point-of-care outcome assessment in the cancer clinic: Audit of data quality. Radiotherapy and Oncology, 2010, 95, 339-343.	0.6	105
238	Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2010, 16, 1129-1139.	7.0	353
239	Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. Journal of Clinical Oncology, 2010, 28, 2996-3001.	1.6	683
240	Acute and Late Radiation Therapy Effects. , 2009, , 179-200.		0
241	Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma. Clinical Cancer Research, 2009, 15, 3716-3724.	7.0	33
242	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. Journal of Clinical Oncology, 2009, 27, 6213-6221.	1.6	289
243	TNMâ€based stage groupings in head and neck cancer: Application in cancer of the hypopharynx. Head and Neck, 2009, 31, 1-8.	2.0	28
244	Prognostic factors in malignancy of the minor salivary glands. Head and Neck, 2009, 31, 58-63.	2.0	42
245	Predictive value of tumor thickness for cervical lymphâ€node involvement in squamous cell carcinoma of the oral cavity. Cancer, 2009, 115, 1489-1497.	4.1	306
246	Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma. Cancer, 2009, 115, 3254-3261.	4.1	144
247	Radiotherapy or surgery for head and neck squamous cell cancer. Cancer, 2009, 115, 5711-5722.	4.1	44
248	Towards further understanding of prognostic factors for head and neck cancer patients: The example of hypopharyngeal cancer. Laryngoscope, 2009, 119, 696-702.	2.0	18
249	Truths and Myths About Radiotherapy for Verrucous Carcinoma of Larynx. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1110-1115.	0.8	39
250	A Device and Procedure for Immobilization of Patients Receiving Limb-Preserving Radiotherapy for Soft Tissue Sarcoma. Medical Dosimetry, 2009, 34, 243-249.	0.9	23
251	Bone Fractures Following External Beam Radiotherapy and Limb-Preservation Surgery for Lower Extremity Soft Tissue Sarcoma: Relationship to Irradiated Bone Length, Volume, Tumor Location and Dose. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1119-1124.	0.8	109
252	Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Review of Anticancer Therapy, 2009, 9, 1145-1157.	2.4	41

#	Article	IF	Citations
253	Adenoid cystic carcinoma of the larynx: A 40â€year experience. Head and Neck, 2008, 30, 919-924.	2.0	47
254	Mucosal melanomas of the head and neck: The Princess Margaret Hospital experience. Head and Neck, 2008, 30, 1325-1331.	2.0	128
255	Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head and Neck, 2008, 30, 1607-1614.	2.0	93
256	The Natural History of Patients With Squamous Cell Carcinoma of the Hypopharynx. Laryngoscope, 2008, 118, 1362-1371.	2.0	195
257	Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: Quality of life in a prospective phase I/II trial. Radiotherapy and Oncology, 2008, 87, 181-187.	0.6	40
258	A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiotherapy and Oncology, 2008, 87, 173-180.	0.6	28
259	Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSVÎ”51) Combined with Radiation for Nasopharyngeal Carcinoma. Clinical Cancer Research, 2008, 14, 4891-4897.	7.0	16
260	Multidisciplinary Management of Soft-Tissue Sarcoma. Radiographics, 2008, 28, 2069-2086.	3.3	58
261	Validation of automatic landmark identification for atlas-based segmentation for radiation treatment planning of the head-and-neck region. Proceedings of SPIE, 2008, , .	0.8	7
262	Lack of influence of intravenous contrast on head and neck IMRT dose distributions. Acta OncolÃ³gica, 2008, 47, 90-94.	1.8	25
263	Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiotherapy and Oncology, 2007, 85, 7-16.	0.6	64
264	Interpreting clinically significant changes in patient-reported outcomes. Cancer, 2007, 110, 196-202.	4.1	237
265	Nasopharynx Cancer: Therapeutic Value of Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, S118-S121.	0.8	34
266	The Surgical and Functional Outcome of Limb-Salvage Surgery With Vascular Reconstruction for Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2005, 12, 1102-1110.	1.5	92
267	The Indications for and the Prognostic Significance of Amputation as the Primary Surgical Procedure for Localized Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2005, 12, 10-17.	1.5	84
268	Techniques to modulate radiotherapy toxicity and outcome in soft tissue sarcoma. Current Treatment Options in Oncology, 2003, 4, 453-64.	3.0	23
269	Recent advances in radiotherapy for soft-tissue sarcoma. Current Oncology Reports, 2003, 5, 274-281.	4.0	38
270	Preoperative Radiotherapy for Adult Head and Neck Soft Tissue Sarcoma: Assessment of Wound Complication Rates and Cancer Outcome in a Prospective Series. World Journal of Surgery, 2003, 27, 875-883.	1.6	59

#	Article	IF	Citations
271	New TNM staging criteria for head and neck tumors. Journal of Surgical Oncology, 2003, 21, 30-42.	1.4	103
272	Staging and prognostic factor evaluation in soft tissue sarcoma. Surgical Oncology Clinics of North America, 2003, 12, 333-353.	1.5	24
273	Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States. Journal of Clinical Oncology, 2003, 21, 496-505.	1.6	84
274	Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet, The, 2002, 359, 2235-2241.	13.7	1,340
275	Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Annals of Surgical Oncology, 2002, 9, 346-354.	1.5	201
276	Initial Results of a Trial of Preoperative External-Beam Radiation Therapy and Postoperative Brachytherapy for Retroperitoneal Sarcoma. Annals of Surgical Oncology, 2002, 9, 346-354.	1.5	14
277	Prognostic factors in clinical decision making. Cancer, 2001, 91, 1688-1695.	4.1	34
278	A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer, 2001, 92, 1484-1494.	4.1	54
279	A Matched Control Study of Treatment Outcome in Young Patients With Squamous Cell Carcinoma of the Head and Neck. Laryngoscope, 1999, 109, 249-258.	2.0	90
280	Neurogenic Sarcomas: Experience at the University of Toronto. Neurosurgery, 1998, 43, 56-64.	1.1	81
281	Functional Outcome in Limb-Salvage Surgery for Soft Tissue Tumours of the Foot and Ankle. Sarcoma, 1997, 1, 67-74.	1.3	39
282	Post-transplantation lymphoproliferative disease. , 0, , 809-811.		0
283	Level of evidence, guidelines and standards. , 0, , 12-22.		0